GLP-1 receptor agonist (GLP-1RA) medications have transformed the treatment of type 2 diabetes (T2D) and obesity, with robust evidence for cardiovascular and renal benefits. The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.